206 related articles for article (PubMed ID: 34241566)
1. Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 - 2021.
Anduran E; Dubois LJ; Lambin P; Winum JY
Expert Opin Ther Pat; 2022 Jan; 32(1):1-12. PubMed ID: 34241566
[TBL] [Abstract][Full Text] [Related]
2. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.
Lindsay D; Garvey CM; Mumenthaler SM; Foo J
PLoS Comput Biol; 2016 Aug; 12(8):e1005077. PubMed ID: 27560187
[TBL] [Abstract][Full Text] [Related]
3. Precise gliomas therapy: Hypoxia-activated prodrugs sensitized by nano-photosensitizers.
Zhang H; Shi C; Han F; Li M; Ma H; Sui R; Long S; Sun W; Du J; Fan J; Piao H; Peng X
Biomaterials; 2022 Oct; 289():121770. PubMed ID: 36075142
[TBL] [Abstract][Full Text] [Related]
4. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
Phillips RM
Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
[TBL] [Abstract][Full Text] [Related]
5. Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.
Su MX; Zhang LL; Huang ZJ; Shi JJ; Lu JJ
Curr Drug Targets; 2019; 20(6):668-678. PubMed ID: 30468124
[TBL] [Abstract][Full Text] [Related]
6. Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.
Mistry IN; Thomas M; Calder EDD; Conway SJ; Hammond EM
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1183-1196. PubMed ID: 28721903
[TBL] [Abstract][Full Text] [Related]
7. Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an in silico approach.
Yilmaz D; Tuzer M; Unlu MB
Math Biosci Eng; 2022 Aug; 19(11):10941-10962. PubMed ID: 36124576
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.
Hunter FW; Wouters BG; Wilson WR
Br J Cancer; 2016 May; 114(10):1071-7. PubMed ID: 27070712
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia Activated Prodrugs: Factors Influencing Design and Development.
Liang D; Miller GH; Tranmer GK
Curr Med Chem; 2015; 22(37):4313-25. PubMed ID: 26487420
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma.
Ghedira D; Voissière A; Peyrode C; Kraiem J; Gerard Y; Maubert E; Vivier M; Miot-Noirault E; Chezal JM; Farhat F; Weber V
Eur J Med Chem; 2018 Oct; 158():51-67. PubMed ID: 30199705
[TBL] [Abstract][Full Text] [Related]
11. Targeting and Treatment of Tumor Hypoxia by Newly Designed Prodrug Possessing High Permeability in Solid Tumors.
Ikeda Y; Hisano H; Nishikawa Y; Nagasaki Y
Mol Pharm; 2016 Jul; 13(7):2283-9. PubMed ID: 27187083
[TBL] [Abstract][Full Text] [Related]
12. The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrug.
Song P; Yao X; Zhong T; Zhang S; Guo Y; Ren W; Huang D; Duan XC; Yin YF; Zhang SS; Zhang X
Oncotarget; 2016 Jul; 7(30):48467-48480. PubMed ID: 27366947
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumors with hypoxia-activated cytotoxins.
Ahn GO; Brown M
Front Biosci; 2007 May; 12():3483-501. PubMed ID: 17485316
[TBL] [Abstract][Full Text] [Related]
14. Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).
Smith PJ; McKeown SR; Patterson LH
IUBMB Life; 2023 Jan; 75(1):40-54. PubMed ID: 35499745
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.
Bailey KM; Cornnell HH; Ibrahim-Hashim A; Wojtkowiak JW; Hart CP; Zhang X; Leos R; Martinez GV; Baker AF; Gillies RJ
PLoS One; 2014; 9(12):e113586. PubMed ID: 25532146
[TBL] [Abstract][Full Text] [Related]
16. Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.
Mao X; McManaway S; Jaiswal JK; Hong CR; Wilson WR; Hicks KO
Cancer Biol Ther; 2019; 20(9):1258-1269. PubMed ID: 31131698
[TBL] [Abstract][Full Text] [Related]
17. Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape.
Hamis S; Kohandel M; Dubois LJ; Yaromina A; Lambin P; Powathil GG
PLoS Comput Biol; 2020 Aug; 16(8):e1008041. PubMed ID: 32745136
[TBL] [Abstract][Full Text] [Related]
18. Advanced nanotechnology for hypoxia-associated antitumor therapy.
Zhao L; Fu C; Tan L; Li T; Zhong H; Meng X
Nanoscale; 2020 Feb; 12(5):2855-2874. PubMed ID: 31965135
[TBL] [Abstract][Full Text] [Related]
19. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.
Benito J; Shi Y; Szymanska B; Carol H; Boehm I; Lu H; Konoplev S; Fang W; Zweidler-McKay PA; Campana D; Borthakur G; Bueso-Ramos C; Shpall E; Thomas DA; Jordan CT; Kantarjian H; Wilson WR; Lock R; Andreeff M; Konopleva M
PLoS One; 2011; 6(8):e23108. PubMed ID: 21853076
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-Activated Prodrug Derivatives of Carbonic Anhydrase Inhibitors in Benzenesulfonamide Series: Synthesis and Biological Evaluation.
Anduran E; Aspatwar A; Parvathaneni NK; Suylen D; Bua S; Nocentini A; Parkkila S; Supuran CT; Dubois L; Lambin P; Winum JY
Molecules; 2020 May; 25(10):. PubMed ID: 32443462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
